Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Immunome ( (IMNM) ) is now available.
Immunome, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025, where stockholders elected Isaac Barchas and Jean-Jacques Bienaimé as Class II Directors to serve until the 2028 Annual Meeting. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (IMNM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.
Spark’s Take on IMNM Stock
According to Spark, TipRanks’ AI Analyst, IMNM is a Neutral.
Immunome’s stock score is primarily impacted by its financial performance, which is challenged by persistent losses and negative cash flow despite a strong equity position. Technical analysis suggests moderate short-term strength but longer-term challenges, and valuation is constrained by unprofitability. The absence of earnings call data and new corporate events means these factors do not influence the score.
To see Spark’s full report on IMNM stock, click here.
More about Immunome
Immunome, Inc. operates in the biotechnology industry, focusing on the development of antibody therapeutics aimed at treating cancer and infectious diseases.
Average Trading Volume: 1,144,370
Technical Sentiment Signal: Sell
Current Market Cap: $832.7M
Learn more about IMNM stock on TipRanks’ Stock Analysis page.